Millicent Sullivan is a Professor and Associate Chair in Chemical & Biomolecular Engineering at the University of Delaware, and a Joint Professor in Biomedical Engineering at UD. Sullivan graduated from Princeton University with a B.S.E. degree in Chemical Engineering and a Certificate in Engineering Biology in 1998. Subsequently, she attended Carnegie Mellon University as a Clare Boothe Luce Graduate Fellow, where she earned her Ph.D. degree in Chemical Engineering with Professor Todd Przybycien in 2003. As a Ruth L. Kirchstein NIH postdoctoral fellow, Sullivan worked with Professor E. Helene Sage in the Matrix Biology/Hope Heart Program of the Benaroya Research Institute. In 2006, Sullivan moved to the University of Delaware. Her laboratory develops new biomaterials for drug delivery, gene delivery, and tissue engineering, with specific therapeutic targets including metastatic breast cancer, bone repair, wound healing, and cardiovascular repair. Specific fundamental foci include de novo peptide design, peptide and polymer self-assembly, and subcellular processing mechanisms. Sullivan is a faculty member in the Delaware Biomaterials COBRE, a member of the Penn Center for Targeted Therapeutics and Translational Nanomedicine (CT3N), an Affiliate Member of the Delaware Biotechnology Institute, and an Affiliate Faculty in the Department of Biomedical Engineering at UD. She is an AIMBE fellow, member of the Gene and Drug Delivery study section at NIH, and Honorary Professor of Chemical Engineering at the University of Melbourne, and she has been the recipient of awards and honors including the Centennial Professorship, the NSF CAREER Award, and the Merck Faculty Fellow Award.